October 25, 2022
42
10
Click the title above for a link to open the 2022 Pharmaceutical Executive APEX Awards Program in an interactive PDF format.
October 11, 2022
Back Page
42
10
Reaching new heights in sustainability a win-win for industry.
October 11, 2022
Features
42
10
Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.
October 11, 2022
Features
42
10
Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
October 11, 2022
Executive Profile
42
10
Bristol Myers Squibb commercial head Chris Boerner believes a straightforward formula is the best formula in advancing innovation and developing talent in today’s complex healthcare climate—an approach he roots in authenticity and “not over engineering,” whether tackling business or culture.
October 11, 2022
Finance
42
10
As fundamentals improve, potential rate plateau could ignite growth.
October 11, 2022
Managed Markets
42
10
Different paths to formulary decision-making.
October 11, 2022
DE&I
42
10
Three simple ways to build trust—by reaching outside your comfort zone.
October 11, 2022
APAC
42
10
Global go-to-market strategies in region require a revamped gameplan.
October 11, 2022
Europe Report
42
10
Patient safety and data protection concerns highlight hesitancy.
October 11, 2022
Washington Report
42
10
FDA backs joint reviews and common research policies around world.
October 11, 2022
From the Editor
42
10
Top hubs continue to perform despite financial uncertainty in other industries.
October 11, 2022
Issue PDF
42
10
Click the title above for a link to open the Pharmaceutical Executive October 2022 issue in an interactive PDF format.
August 17, 2022
Features
42
10
How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.